Articles
16 June 2009
Vol. 2 No. 15: Secondary Leukemias and leukemogenesis Rome, 3-4 November 2006
https://doi.org/10.4081/hmr.v2i15.613

Low dose Azanucleosides for high risk (s)MDS and AML

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
216
Views
244
Downloads

Authors

P.W. Wijermans
support@pagepress.org
Azanucleosides like 5-aza- 2’deoxycytidine (Decitabine= Dacogen) and 5-azacytidine (Vidaza) are both cytosine analogues, already synthesised in1964, tested for there cytotoxic capacity when applied in high doses. Using high dose Decitabine therapy for AML patients it became clear that there was a good antileukemic activity but also a high toxicity.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Low dose Azanucleosides for high risk (s)MDS and AML. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(15). https://doi.org/10.4081/hmr.v2i15.613